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ABSTRACT
Notch-1 and osteopontin (OPN) mediate angiogenesis and glioma stem-like 
cell (GSLC) maintenance. However, the relationship between these molecules and 
GSLCs during the development of glioma is unknown. We investigate the expression 
of Notch-1, OPN and vascular endothelial growth factor (VEGF) associated to the 
stemness markers nestin and CD133 in three stages of murine gliomas induced by 
N-ethyl-N-nitrosourea (ENU).
Notch-1 and OPN overexpress in the intermediate stage (II), which corresponds 
to the “angiogenesis switch”. Nestin+ cells appear in all stages of ENU-glioma but 
CD133 only from stage II on. In stage III, neoplastic cells expressing nestin, CD133 
and nestin/CD133 reside in spheroid-like aggregates (SAs) and in the neoangiogenic 
border. These aggregates show Notch-1 and VEGF+ surrounding cells and a significant 
size and density increase with respect to stage I (3.3 ± 1.5 to 22.4 ± 6.3 µm2, nº = 
0.3 ± 0.1 to 4.2 ± 0.9, from stage I to stage III, respectively).
OPN expression increases in correlation to the glioma malignancy from 4.5 ± 1.8%  
(I) to 12.3 ± 1.2% of OPN+ cells (III). It predominates in astrocyte-like cells of 
the neoangiogenic border, displaying co-location with VEGF and CD133. The OPN 
immunopositivity distribution correlates with the CD133 distribution.
In conclusion, OPN co-expressing with CD133 contributes to the identification 
of GSLCs in the neoangiogenic border, while Notch-1 is present around SAs in 
advanced stages. The ENU-glioma, mainly in stage II, is a useful tool for assessing 
new antitumour therapies against these molecules.
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INTRODUCTION
Glioblastoma (GBM) is the most malignant 
solid tumor of the central nervous system (CNS), with 
poor prognosis due to a high proliferative and invasive 
capacity, besides resistance to current therapies [1]. The 
growth of GBM is angiogenesis-dependent, therefore 
several antitumor therapies are focused against this 
process, trying to interfere with molecules that participate 
in this process, such as hypoxia inducible factor 1 alpha 
(HIF-1alpha), vascular endothelial growth factor (VEGF) 
or its receptors (VEGFR2, VEGFR1), erythropoietin 
(EPO) and endothelial nitric oxide synthase (eNOS) [2, 3]. 
Gliomas develop resistance to antiangiogenic molecules 
by mechanisms frequently involving cancer stem cells 
(CSCs) [4, 5]. 
Glioma stem-like cells (GSLCs) represent a small 
subpopulation of cells showing stemness-associated 
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properties and playing a pivotal role in angiogenesis 
[6, 7]. These cells, in addition to the capacity for 
self-renewal and multilineage differentiation [8], are 
responsible for radio-chemo-resistance and subsequent 
tumor recurrence [9]. Osteopontin (OPN) and Notch-1 are 
two molecules proposed as being involved in mediating 
this resistance [10–12].
Notch signalling is an intercellular signalling 
pathway that plays an important role in reprogramming 
neoplastic cells towards the GSLC phenotype [13, 14]. 
To date, four Notch receptors (Notch 1-4) with five 
corresponding ligands namely Delta-like-1, Delta-like-3, 
Delta-like-4, Jagged-1 and Jagged-2, have been identified 
in humans. Notch-1 is a transmembrane receptor involved 
in cell-cell signalling that has been related to glioma 
survival and proliferation [15]. 
OPN has been linked to tumor progression, 
angiogenesis and metastasis formation [16]. It is a 
member of the Small Integrin-Binding Ligand N-linked 
Glycoproteins (SIBLINGs). They are a family of 
extracellular matrix proteins involved in the acquisition/
maintenance of stemness characteristics and tumorigenicity 
of GSLCs [17]. Its overexpression is shown in hypoxia and 
has been related to a poorer prognosis in GBM [18]. 
Consequently, GSLCs and molecules related to 
their maintenance are currently considered a potential 
therapeutic target for antitumor therapies [19]. Despite 
this, the cellular heterogeneity of GBM and the lack of 
specific markers make it difficult to identify GSLCs. 
GSLCs from GBM exhibit different phenotypes, with 
increasing interest in the potential significance of cancer 
stem cells with respect to diagnosis, prognosis and 
development of novel therapeutic targets [20]. 
Several authors use markers of stemness 
(SOX2, OLIG4, CD15, nestin or CD133) to identify 
dedifferentiated neoplastic cells [21–25]. CD133 
(a membrane marker also known as Prominin-1) and 
nestin (a type IV intermediate filament protein) are 
two immunomarkers widely associated with stemness 
phenotype acquisition mediated by hypoxia [26]. The 
microenvironment plays a pivotal role in inducing cell 
dedifferentiation and the stemness phenotype. Wang 
et al. [27] have shown the role played by hypoxia in cell 
dedifferentiation. They marked cells in vitro by CD133-
CD15-Nestin and demonstrated via in vivo assays the 
tumorigenic capacity of these selected cells under hypoxia 
conditions. Nestin and CD133 have been associated 
with GSLCs located in perivascular niches of tumour 
microvessels [28].
In previous work, we have studied the angiogenesis 
process in the ENU-glioma model [2, 29, 30]. ENU 
is a nitrosourea that after prenatal exposure induces 
glial tumours in the central nervous system. It acts by 
alkylating O6-guanine, O2-thymine and O4-thymine, 
inducing mutations of certain oncogenes such as p53 and 
genes coding for caspase-9, platelet-derived growth factor 
receptor alpha (PDGFRα), CDKN2A and EGFR, all related 
to the genesis of glial tumours [31, 32]. Therefore, this 
model reproduces quite closely the natural development 
and neuropathology of human gliomas [30, 33]. 
We described an overexpression of VEGF in the 
intermediate stage of ENU-glioma [30]. This stage, 
which corresponded to the “angiogenesis switch”, was 
characterised by an increase of microvascular density and 
an increase of VEGF+ cells in the border areas and around 
the aberrant microvessels [33]. Nestin as well as CD133 
were expressed in cells located in areas showing features 
of hypoxia and associated with aberrant microvessels, 
conforming clusters called spheroid-like aggregates (SAs) 
[29, 34].
Therefore, in this work, since the Notch-1 and OPN 
molecules are related to the maintenance of angiogenesis 
and GSLCs, we analyze the distribution of Notch-1 and 
OPN immunopositivity in relation to nestin and CD133 
and the proangiogenic factor VEGF in early to advanced 
stages of ENU-gliomas. 
RESULTS 
Expression of Nestin and CD133 markers in 
different stages of ENU-glioma
81 gliomas from 53 rats are segregated into three 
stages of malignancy (n = 27, Table 1) according to 
parameters described in our previous works [30, 33, 34]. 
Stage I corresponds to low-grade glioma. It represents 
small masses of proliferating cells with isomorphic 
morphology that develop mainly inside subcortical white 
matter. Few nestin+ cells are found distributed throughout 
these masses (nestin-LI of 4.8 ± 0.57) (Figure 1A). Stage 
II corresponds to nodules showing anaplastic changes and 
increase of nestin+ cells (nestin-LI of 9.69 ± 0.84). Labelled 
cells appear either inside the tumour or in the border area, 
building aggregates around the microvessels or isolated 
called SAs. (Figure 1B). Nestin+ cells show two different 
morphologies, small round cells similar to stem cells 
and large cells with elongated processes. Stage III is the 
advanced anaplastic glioma corresponding to glioblastoma 
(GBM). This stage shows the highest density of nestin+ 
cells (nestin-LI of 16.67 ± 1.36) (Figure 1A) and a clear 
pattern of distribution in the border area of the tumour. 
Immunoexpression for CD133 is found in small 
round-shaped cells since stage II and it follows the same 
distribution pattern as nestin. In stage III, nestin+, CD133+ 
and nestin/CD133+ cells are found aggregated into SAs 
distributed thorough the neoplasia, in perinecrotic areas 
or close to aberrant microvessels. Tumor border area 
shows plenty of these cells located near the glomeruloid 
vessels and delimiting the periphery area of the neoplasia 
(Figure 1B).
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Figure 1: Nestin expression in ENU-glioma development. (A) Statistical increase of nestin+ cell density during ENU-glioma 
progression, shown graphically. *p < 0.05, **p < 0.01, ***p < 0.001. (B) In stage III, there are nestin+ cells isolated throughout the neoplasia 
or distributed in clusters termed spheroid-like aggregates (SAs, arrow). These clusters are located in the perivascular area of huge dilated 
microvessels. Aggregations of nestin+ cells are also shown in hypoxic areas of pseudopalisading necrosis and in the periphery of the tumor, 
associated with glomeruloid vessels. Scale bar of 50 μm.
Table 1: Characteristics of the three stages of ENU-glioma
Parameters of ENU-glioma classification Stage I Stage II Stage III
Tumour size 
(mm2)
Range
Mean
0.5 to 1.9
1.2 ± 0.3
2.7 to 4.9
3.8 ± 0.5
7.3 to 14.3
10.7 ± 1.6
Proliferation index 
(KI-67 PI, % of cells)
Range
Mean
2.4 to 6.2
4.2 ± 0.5
6.04 to 12.8
9.35 ± 0.8
11.6 to 28
16.8 ± 1.9
Parameters to take into account to segregate the experimental gliomas induced by a single dose of N-ethyl-N-nitrosourea to 
prenatal Sprague Dawley rats.
Abbreviations: KI-67 PI: proliferation index. 
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Spheroid-like aggregates associated cells
SAs are groups of at least six nestin+ neoplastic 
cells with a small round morphology and no cell processes. 
They predominate in stages II and III and their density and 
size increase according to tumour malignancy (Figure 2A, 
2B). The density and size of SAs in neoplasia is several 
fold higher in stage III than in stage I (mean number of 
SAs = 4.2 ± 0.9, 0.36 ± 0.1 and mean size = 22.4 ± 6.3, 3.3 
± 1.5 µm2, respectively). The significant increase is found 
in stage II with respect to stage I (p < 0.05). Distribution 
of stemness markers in SAs also varies according to 
glioma malignancy. The smallest SAs (stage I) show a 
few nestin+ cells. More neoplastic cells stained by nestin 
and a few cells positive for CD133 are found in SAs 
from stage II. At this intermediate stage, nestin staining 
is also shown in large cells with cell processes. However, 
CD133 immunoexpression is only observed in the soma 
of small cells. The largest SAs (stage III) display different 
populations of cells: small round cells that express nestin, 
CD133 and nestin/CD133 (Figure 2C) and numerous 
GFAP+ astrocytes with long processes surrounding SAs. 
The majority of the astrocytes co-localize with VEGF. 
Indeed, a few of the astrocyte processes are marked with 
nestin (Figure 2D).
Hypoxic cell distribution related to CD133 
expression
Quantitative results from the “hidroxyprobe” 
assay show a decrease of hypoxic cell density between 
stages I-II and a great increase from II to III (Figure 3A). 
Although stage III presents the highest density of hypoxic 
cells (Hypoxic-LI of 61.3 ± 13.8%), no differences 
among groups are found. Morphologically, positive 
scattered neoplastic cells are distributed throughout the 
proliferative mass in the initial stage (I), while in the most 
malignant stage (III), numerous strongly positive cells are 
accumulated in hypoxic areas such as pseudopalisading 
necrosis or around aberrant microvessels (Figure 3B). In 
stages II and III some of these hypoxic cells show CD133 
expression as well (Figure 3C).
Notch-1+ undefined cells in advanced ENU-
glioma stages
Notch-1 immunopositivity is observed in cell 
processes of undefined cells distributed in the tumour 
border and around large SAs of stages II–III. Notch-1 
co-expression with other antibodies used in this work is 
not detected (Figure 4). 
Figure 2: Quantitative and inmunofluorescence study of spheroid-like aggregates (SAs). (A–B) Graphics show the 
enhancement of their density and size during the ENU-glioma progression. There is no significant difference between stage II and III. 
*p < 0.05, **p < 0.01, ***p < 0.001. (C) SAs showing a high density of small round neoplastic cells. Some of them express nestin (green), 
CD133 (red) and nestin/CD133 (yellow). (D) VEGF stain is mainly shown in astrocytes located externally to SAs. Few nestin+ cell 
processes share VEGF positivity (yellow). Scale bar of 50 μm. 
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OPN overexpression in the border area of  
stage III
OPN immunoexpression is found in all glioma 
stages. There is an increase in OPN-LI according to 
malignancy, being statistically significant between stages 
I–III and II–III (p < 0.001 and p < 0.05, respectively). 
Distribution of OPN+ cells within gliomas displays a 
few small OPN+ cells (OPN-LI of 4.5 ± 1.8%) dispersed 
inside the proliferative mass in stage I, while OPN+ 
large cells in stages II and III (OPN-LI of 7.7 ± 0.8% and 
12.3 ± 1.2%, respectively) predominate on the border. 
Stage III shows some OPN+ small cells with scarce 
cytoplasm and no cellular processes inside the tumour, 
coexisting with some OPN+ cells with large cytoplasm 
and numerous cell processes as well as some large cells 
distributed adjacent to the microvasculature (Figure 5A). 
In the border area, there are abundant GFAP+ astrocyte-
like cells occupying the 18.68 ± 3.22% of total surface. 
A few of them co-localize with OPN, VEGF and OPN/
Figure 3: Detection of tissue hypoxia in ENU-glioma by Pimonidazole hydrochloride (Hydroxyprobe™-1 solution; 
Chemicon). (A) Graphic representation of hypoxic cell density in three stages of ENU-glioma development. *p < 0.05, **p < 0.01, ***p < 
0.001. (B) Hypoxic cell distribution in stage III shown by DAB, in perinecrotic palisade and surrounding the endothelium of dilated vessels. 
(C) Confocal immunofluorescence images showing hypoxyprobe (green) and CD133 (red) staining identifying the presence of GSLCs in 
hypoxic tumour areas of stage III. Numerous hypoxic cells co-express with CD133 (yellow), forming aggregates of neoplastic cells within 
the tumour and the perivascular area of aberrant vessels. Scale bar of 50 μm.
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VEGF. Immunoexpression of OPN is statistically less 
than VEGF (1.4 ± 0.17% and 5.48 ± 1.9%, p = 0.011) 
(Figure 5B). Nestin and CD133 immunoexpression is also 
found in this area, being nestin expression significantly 
higher than that of CD133 (p = 0.042). Moreover, 
quantitative study reveals no statistical differences 
between nestin and VEGF expression, nor between OPN 
and CD133 expression. Most nestin+ cells co-express 
VEGF and most OPN positive cells co-express CD133 
(Figure 5B).
DISCUSSION 
Previous studies have suggested that GSLCs are 
involved in angiogenesis and glioma progression [2, 7, 35]. 
Thus, understanding the mechanisms underlying the 
maintenance of GSLCs is crucial for the development of 
antiangiogenic therapies. In this study, we investigate the 
association between two molecules involved in glioma 
neoangiogenesis, OPN and Notch-1, and two stem cell 
markers, nestin and CD133. 
In ENU-gliomas, in a similar way to human brain 
tumors, histological heterogeneity with hierarchical 
differentiation potential is shown [36]. Various cell 
populations have different capacities for tumor growth 
depending on their undifferentiating status [37]. The 
immunostaining against Nestin or CD133 allows us to 
identify a subgroup of small round cells with no processes, 
suggesting they are in a stemness state or phase, and another 
subgroup of differentiated large cells with numerous 
processes [38]. 
The expression of both markers increases during 
the development of ENU-induced gliomas, corroborating 
their prognostic significance [39]. Immunopositive cells 
for CD133 appear in more advanced stages than nestin 
ones do. Moreover, results reveal that cells co-expressing 
nestin/CD133 tend to aggregate in hypoxic niches. Some 
authors state that interconversion between non-CSCs and 
CSCs could be shifted in one way or another in response 
to specific microenvironmental factors, such as hypoxia, 
acidic stress, and metabolic stress [40]. In various tumors, 
hypoxia influences the dedifferentiation of cells and 
acquisition of nestin/CD133 positivity [27, 41]. 
Notch-1 and spheroid-like aggregates
Before angiogenesis starts, neoplastic cells have 
to acquire a determined phenotype [42]. In addition, the 
tumoural microvasculature experiments changes related 
to the relative tissue hypoxia taking place, which leads to 
distorted microvessels, irregular regional blood flow and 
disturbed Blood-Brain Barrier function. Consequently, 
intratumoral blood perfusion is altered and tissue hypoxia 
increases [29, 34].
Hypoxia induces Notch signalling, which in turn 
promotes and reprograms malignant cells towards GSLC 
phenotype [43]. Hypoxic pre-conditioning status could be 
mediated by HIF-1alpha and Notch-1 pathway [26, 44]. In 
advanced stages of ENU-glioma (II, III), hypoxic cells are 
found inside pseudopalisading necrosis and around bulk 
aberrant microvessels. These abnormal vascular niches 
mimic the normal neural stem-cell niches and promote 
proliferation of the GSLCs, housing and protecting them 
[45]. Thus, next to and even around these vessels, SAs are 
found [30]. 
SAs resemble the in vitro tumour spheres where 
different cell populations co-exist. In our previous 
work, we described Nestin+, CD133+, CD133/nestin+ 
cells and neighbouring supportive cells like astrocytes 
expressing GFAP and VEGF [30]. Now, we can include 
overexpression of Notch-1 in cells adjacent to these 
structures. Notch-1 and VEGF may be microvascular 
niche-derived factors that actively maintain the stem-
like state and promote proliferation [45, 46]. Similar 
cell aggregates have been previously described using 
histochemistry for butyrylcholinesterase (BChE) [29]. 
Figure 4: Co-expression study of Notch-1 (red) and nestin (green) in stage III. (A) Distribution of Notch-1+ cells with 
fusiform morphology detected in the peripheral area of the tumour. (B) Notch-1+ elongated cell processes of undefined cells around SAs. 
There is no co-expression with nestin antibody. Scale bar of 50 μm.
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This choline esterase has a very relevant function in 
neurobiology as a growth factor, being involved in cell 
proliferation and differentiation [47]. 
Notch-1 and VEGF are overexpressed in ENU-
glioma intermediate stage (II), corresponding to 
angiogenesis switch; in parallel, there is a significant 
increase in size and density of SAs [2, 30]. These 
findings could explain the role of Notch-1 and its ligands 
in glioma survival and proliferation mediated by stem-
like cells [14]. Moreover, it is known that expression of 
Notch-1 and VEGF is induced by hypoxia. Therefore, 
hypoxia is crucial for the survival of stem-like cells and 
modulation of these niche microenvironment factors 
[48]. Stem-like cells and SAs are adaptive changes 
in order to survive in adverse microenvironmental 
conditions.
OPN in the neoangiogenic area of ENU-
glioblastoma
OPN has been widely associated with tumour 
progression, development of metastasis and characteristic 
resistance to treatment of cancer stem cells [49]. This 
glycoprotein has been identified as a prognostic factor in 
human GBM [50]. We corroborate this property in the ENU-
glioma model, finding an early onset of OPN expression 
in a few cells displayed in stage I, which increases during 
neoplastic development, and tends to cluster in the border 
of the glioma, reaching its highest expression in stage III.
The peripheral area of ENU-GBM (stage III) was 
characterized as a neoangiogenic border because of 
VEGF overexpression and microvascular proliferation 
[30, 33]. Aggregates of some nestin+, CD133+ 
Figure 5: Study of OPN immunoexpression in ENU-glioma stages of development. There is an enhancement of the density of 
OPN+ cells corresponding to ENU-glioma malignant process. (A) In advanced stages II–III, these cells present different morphologies, as 
shown by DAB. Small round shape cells, cells of large soma and elongated cells contacting with a tumour microvessel is found within the 
neoplasia. (B) In the periphery area of stage III, many astrocyte-like cells tend to cluster. Confocal images of double immunofluorescence 
show positivity of astrocyte-like cell for OPN, nestin (green); VEGF, GFAP, and CD133 (red) (Hoechst counterstained, blue). Some 
of OPN+ cells and some of nestin+ cells co-express with GFAP, VEGF and CD133 (yellow). OPN expression is similar to CD133 but 
significantly lower than GFAP, VEGF and nestin one. Nestin is significantly lower than GFAP but similar to VEGF. Graphics show 
the osteopontin labelling index as mean percentage of positive cells (A) and quantitative study of the immunoexpression of the studied 
antibodies as mean percentage of border surface occupied by positive cells (B) ± typical error. *p < 0.05, **p < 0.01, ***p < 0.001. Bar scale 
of 10 μm (A) and 50 μm (B). 
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and nestin/CD133+ elongated cells associated with 
endothelial cells were described in this area [29, 34]. 
In common with some other authors, we proposed 
that these nestin+ and CD133+ cells may be selected 
cells with invasiveness and proliferative capacity 
which use the extracellular matrix of the vessel wall to 
migrate and infiltrate the brain parenchyma [51, 52]. 
Now, in the present work, we describe numerous 
astrocyte-like cells near to glomeruloid vessels that 
overexpress OPN and also the stemness markers nestin 
and CD133. It could be another fraction of nestin/CD133+ 
neoplastic cells, already described by Wang et al. (2010), 
related to endothelial differentiation, and not with a 
migratory or invasive role [51]. They could be involved 
in the angiogenesis process, generating tumor vessel 
prolongation [52]. Moreover, in the neoangiogenic area 
of ENU-GBM, some astrocyte-like cells co-express OPN/
VEGF. It has been reported that OPN acts synergically 
with VEGF, as they induce the expression of one another 
in tumor cells [53]. Experimental evidence suggests that 
OPN may affect angiogenesis by endothelial cells directly 
via PI3K/AKT- and ERK-mediated pathways with VEGF 
acting as a positive feedback signal [54]. In the ENU-
glioma model, we have shown a close relationship 
between tumor microvascular endothelium, eNOS, 
VEGF and the angiogenesis process [55]. Adding to the 
above, this recent study describes expression of OPN 
in cells attached to the tumor microvascular network. 
Considering this, we agree with Wang et al. (2011) that 
upregulation of OPN in glioma cells could stimulate 
formation of vascular endothelial cells via activation of 
VEGF and the avβ3/PI3-K/AKT/eNOS/NO-dependent 
signaling pathway [56]. 
In summary, our findings reveal that Notch-1 
and OPN are overexpressed in the intermediate (II) and 
advanced (III) stages of ENU-gliomas. Both molecules 
have a relationship with VEGF. In these stages, there 
is a significant increase of cell aggregates composed 
of populations of cells expressing nestin+, CD133+ or 
nestin/CD133+ simultaneously. Notch-1 and VEGF 
are distributed around these cell aggregates. Thus, they 
would actively contribute to maintaining the stem-
like state and proliferation capacity of GSLCs [57, 58]. 
On the other hand, we also demonstrate that OPN and 
VEGF are overexpressed in the neoangiogenic border, 
where the area immunopositive for VEGF is significantly 
higher than that for OPN. Moreover, the immunopositive 
area for OPN is very similar to that positive for CD133, 
and the VEGF-positive area is similar to the nestin one. 
Some areas display co-expression of OPN/CD133. These 
findings corroborate that OPN and VEGF are involved in 
glioma progression mediated by GSLCs [53, 54, 56, 58]. 
That supports the interest in GSLCs, OPN and Notch-1 as 
possible targets for the treatment of GBM. Intermediate 
stage ENU-glioma could be a good tool to develop new 
antitumour therapeutic strategies.
MATERIALS AND METHODS
Experimental animal tumor model and 
hydroxyprobe assay
6 Sprague-Dawley adult rats were intraperitoneally 
injected with a single dose of N-ethyl-N-nitrosourea 
(ENU, 80 mg/kg.b.w, 10 mg/ml in 0.9% NaCl; E2129, 
Sigma-Aldrich, Spain) at 15th day of pregnancy. 
Offspring rats were analyzed every two days from 4th 
to 10th of rat age to establish their health status and to 
identify neurological clinical sings. The health status 
was recorded taking into account abnormal postures, 
abnormal vocalizations, unusual weight loss, and extreme 
immobility or swallow eyes. Rats were asymptomatic 
until 6 month of age. The most relevant neurological signs 
recorded were: lateralization of the head, ataxia, anxiety 
and increase of rearing. Symptoms progressed with the rat 
age and they could come to show severe symptoms, such 
as numbness, apathy, seizures and death. 
In line with our previous work, to detect the glioma 
neoplasia, offspring rats were sacrificed monthly between 
6 to 10 months old. Fifty-three of these rats that displayed 
glioma were selected for this study. A quarter of the 
animals display a multifocal location of neoplasia.
Four hours prior to euthanasia, 11 animals were 
intraperitoneal injected with 60 μg/kg.b.w. of Pimonidazole 
hydrochloride (60 μg/mg, Hydroxyprobe™-1 solution; 
Chemicon). 
All experimental methods were carried out 
following the Spanish Royal Decree 1201/2005 BOE 
published October 21st 2005, and the 2003/65/CE from 
the European Parliament and Council of July 2003. 
The Ethical Committee for Animal Welfare (CEBA) 
of the University of the Basque Country, Leioa, Spain 
(CEBA/154/2010/) approved the protocols.
ENU-glioma screening
Gliomas were in vivo identified by magnetic 
resonance imaging (MRI, Biospec BMT 47/40, Bruker, 
Ettlingen, Germany). To aid in tumor visualization, 
animals were injected i.p. with 1.5 ml/kg b.w. of 
gadolinium (Gd-DTPA) (Magnevist, Schering). 
Then rats were transcardially perfused with 2% 
PFA, their brains were removed and immersed in the 
same solution at 4° C overnight. Tumors were detected 
by stereoscopic microscopy (Lan Optics). Some coronal 
sections including the tumor were embedded in paraffin 
wax (Histosec® Merck) and others were stored in 30% 
sucrose until the tissues sink. 
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Evaluation of tumour size and histologic analysis
For the histopathological study, hematoxylin-eosin 
(H&E) staining was carried out on 4 mm sections. Sections 
were observed for the presence of histological features, 
such as cellular anaplasia, atypical mitosis, microvascular 
proliferation, hemorrhages, necrosis or cysts. The tumor 
area was measured using a reticule of 62,500 μm2 (at × 40 
magnification) as our previous work [33, 34]. 
Immunohistochemistry
Immunohistochemical assay was carried out on 
4 μm sections against nestin (mouse monoclonal, 1:200; 
sc-33677, Santa Cruz, CA), osteopontin (OPN, mouse 
monoclonal, 1:200; sc-21742, Santa Cruz, CA) and Ki-
67/MIB-5 (Clone MIB-5; mouse monoclonal, 1:100; 
M7248, Dako, Denmark) using the conventional ABC 
method (Elite ABC Kit, Vector Laboratories, Burlingame, 
CA). In the case of the Pimonidazole hydrochloride, the 
manufacturer’s protocol was followed (Hydroxyprobe™-1 
solution; Chemicon, USA). The reaction product was 
developed by 3.3-diamino-benzidine (DAB, 0.25 mg/ml; 
8001, Sigma-Aldrich, Spain) and H2O2 (0.01%) followed 
by haematoxylin counterstaining. Sections were finally 
dehydrated and covered with DPX mounting medium 
(Sigma-Aldrich, Spain). Negative controls in which the 
primary antiserum was omitted were also included in each 
staining run.
To assess the co-expression of the different markers, 
double staining was carried out in free-floating sections. 
Briefly, 40 μm free-floating sections were incubated with 
blocking solution (10% BSA, 3% Triton X-100 in 0.1 M 
PBS) for 2 h. Then they were incubated overnight at room 
temperature with a cocktail of primary antibodies in 1% 
BSA containing 0.1% Triton X-100. Primary monoclonal 
antibodies used were nestin (1:400; sc-21247, Santa 
Cruz, CA) and osteopontin (OPN, 1:300; sc-21742, Santa 
Cruz, CA). Polyclonal antibodies are vascular endothelial 
growth factor (VEGF, 1:200; sc-152, Santa Cruz, CA), 
GFAP (1:400; sc-6170, Santa Cruz, CA), CD133 (1:100; 
ab-16518 Abcam, Cambridge, UK), Glucose transporter 1 
(GluT-1, 1:200; 07-1401, Merck Millipore, Germany) and 
Notch-1 (1:200; bs-1335R Bioss Antibodies Inc., USA). 
Subsequently, sections were incubated for 2 h with a 
cocktail of secondary fluorescent antibodies: Alexa Fluor 
568 and 488 (1:400, Invitrogen, Spain). Then, sections 
were incubated with Hoechst solution for 10 min. Finally, 
sections were rinsed, mounted on gelatin-coated slides and 
cover-slipped in an aqueous medium (Vectashield Mounting 
Medium H-100). Primary antibodies were omitted for 
control samples. Images were acquired with Olympus 
Fluoview FV 500 confocal fluorescence microscopy using 
sequential acquisition to avoid overlapping of fluorescence 
emission spectra. The images were treated with FV 10-ASW 
1.6 Viewer and Adobe Creative Suite 4. 
Quantitative studies
Mean number of positive cells for nestin (nestin-
LI, labelling index), osteopontin (OPN-LI) and Ki-67 
(PI, tumour proliferation index) were calculated in 81 
gliomas and mean density of hypoxic cells (Hypoxic-LI) 
in 11 gliomas. To calculate these indexes, we followed 
the protocol described by Bulnes & Lafuente [30, 33]. 
400 tumour cell nuclei were counted at high magnification 
(×400) from the more representative area of the tumour, 
and the percentage of cells expressing the antigen in 
any way was reported. The quantitative evaluation was 
performed by the same researcher to avoid inter-observer 
variability. Only positive cells not adhered to vessels or 
cells are individually localized not forming aggregates 
were counted.
Measurements of SAs (aggregation of 6 or more 
nestin+ cells), were performed in sections from 81 gliomas 
following our previous work [34]. The parameters of SAs 
analyzed were: incidence (% of tumors displaying one 
or more SAs), density (mean number of SAs per mm2 
of tumor) and size (mean area occupied by the SAs, 
expressed in μm2). The measurements were carried out 
using Image J program (1.48 n) and the mean value per 
ENU-glioma stage was calculated.
Immunoexpression of OPN, VEGF, GFAP, nestin 
and CD133 was analysed in confocal photomicrographs 
(pixel size of 32181 μm2) from 7 samples of the border 
area of stage III. The area occupied by the cells stained by 
these antibodies was measured using Fiji-win64 program. 
Values were expressed as the percentage of area stained in 
101249 μm2 of tumour border. 
Statistical analyses
All statistical data were analyzed using SPSS 
statistical software (version 23.0 from IBM, Spain). Prior 
to analysis, data was examined for normal distribution 
using the Kolmogorov-Smirnov test and for homogeneity 
of variances using Levene’s test. To compare the 
parameters studied in the three different ENU-glioma 
stages we used two-way ANOVA with posthoc analysis 
(posthoc tests use the Bonferroni correction for equal 
variances or Tamhane’s T2 correction for unequal 
variances). Data was described as mean ± typical error. 
Significance was declared at p < 0.05.
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